EUVIMEDEUVIMED entdecken
LeserbriefKohortenstudieOpen Access · CC BY 4.0

Germline biallelic BRCA2 pathogenic variants and medulloblastoma: an international cohort study

Svenja Kastellan, Reinhard Kalb, Bia Sajjad, Lisa J McReynolds, Neelam Giri, David Samuel, Till Milde, Miriam Elbracht, Susanne Holzhauer, Marena R Niewisch, Christian P Kratz

Journal of Hematology & Oncology · 2024

DOI: 10.1186/s13045-024-01547-4 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Journal of Hematology & Oncology, 2024. Verfasst von Svenja Kastellan und 10 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany. Hauptthemen laut MEDLINE: BRCA2 Protein, Medulloblastoma, Germ-Line Mutation, Fanconi Anemia. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bundesministerium für Bildung und Forschung, Deutsche Kinderkrebsstiftung, Intramural Research Program of the Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Constitutional heterozygous pathogenic variants in genes coding for some components of the Fanconi anemia-BRCA signaling pathway, which repairs DNA interstrand crosslinks, represent risk factors for common cancers, including breast, ovarian, pancreatic and prostate cancer. A high cancer risk is also a main clinical feature in patients with Fanconi anemia (FA), a rare condition characterized by bone marrow failure, endocrine and physical abnormalities. The mainly recessive condition is caused by germline pathogenic variants in one of 21 FA-BRCA pathway genes. Among patients with FA, the highest cancer risks are observed in patients with biallelic pathogenic variants in BRCA2 or PALB2 . These patients develop a range of embryonal tumors and leukemia during the first decade of life, however, little is known about specific clinical, genetic and pathologic features or toxicities. Here, we present genetic, clinical, pathological and treatment characteristics observed in an international cohort of eight patients with FA due to biallelic BRCA2 pathogenic variants and medulloblastoma (MB), an embryonal tumor of the cerebellum. Median age at MB diagnosis was 32.5 months (range 7–58 months). All patients with available data had sonic hedgehog-MB. Six patients received chemotherapy and one patient also received proton radiation treatment. No life-threatening toxicities were documented. Prognosis was poor and all patients died shortly after MB diagnosis (median survival time 4.5 months, range 0–21 months) due to MB or other neoplasms. In conclusion, MB in patients with biallelic BRCA2 pathogenic variants is a lethal disease. Future experimental treatments are necessary to help these patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BRCA2 ProteinMedulloblastomaGerm-Line MutationFanconi AnemiaHumansMaleChild, PreschoolFemaleInfantCohort StudiesCerebellar NeoplasmsAlleles

Stichwörter der Autor:innen

BRCA2Fanconi anemiaMedulloblastoma

Substanzen

BRCA2 ProteinBRCA2 protein, human

Autor:innen und Institutionen

  • Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany.
  • Department of Human Genetics, University of Würzburg, Biocenter, Würzburg, Germany.
  • Clinical Genetics Branch Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
  • Department of Hematology-Oncology, Valley Children's Hospital, Madera, CA, USA.
  • Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
  • Clinical Cooperation Unit Pediatric Oncology, German Cancer Research Center (DKFZ), German Consortium for Translational Cancer Research (DKTK), Heidelberg, Germany.

Förderung

  • Bundesministerium für Bildung und Forschung
  • Deutsche Kinderkrebsstiftung
  • Intramural Research Program of the Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA
  • Gerdes Stiftung, Germany

Zitieren

APA

Kastellan, S., Kalb, R., Sajjad, B., McReynolds, L. J., Giri, N., Samuel, D., Milde, T., Elbracht, M., Holzhauer, S., Niewisch, M. R., & Kratz, C. P. (2024). Germline biallelic BRCA2 pathogenic variants and medulloblastoma: an international cohort study. Journal of Hematology & Oncology. https://doi.org/10.1186/s13045-024-01547-4

Vancouver

Kastellan S, Kalb R, Sajjad B, McReynolds LJ, Giri N, Samuel D, et al. Germline biallelic BRCA2 pathogenic variants and medulloblastoma: an international cohort study. Journal of Hematology & Oncology. 2024. doi:10.1186/s13045-024-01547-4

BibTeX
@article{Kastellan2024,
  author = {Kastellan, Svenja and Kalb, Reinhard and Sajjad, Bia and McReynolds, Lisa J and Giri, Neelam and Samuel, David and Milde, Till and Elbracht, Miriam and Holzhauer, Susanne and Niewisch, Marena R and Kratz, Christian P},
  title = {Germline biallelic BRCA2 pathogenic variants and medulloblastoma: an international cohort study},
  journal = {Journal of Hematology & Oncology},
  year = {2024},
  doi = {10.1186/s13045-024-01547-4}
}
Kostenlos starten →